News
|
|
Cloud Pharmaceuticals CEO and CSO to Speak at AI Pharma Innovation, July 26-27, 2017 in Boston.
Research Triangle Park, NC (July 17, 2017) -- Cloud Pharmaceuticals, a cloud-based drug design and development company, is pleased to announce that company CEO Ed Addison and CSO Shahar Keinan will be featured as speakers at AI Pharma Innovation Summit 2017 taking place July 26 and 27, 2017 in Boston. AI Pharma Summit is the first industry specific conference focused on the challenges in the adoption and application of AI technology in pharma. They are scheduled to speak on Thursday, July 27, 2017 as follows:
Shahar Keinan, CSO, Cloud Pharmaceuticals:
- 10:00 AM: Keinan will present "Discover: Showcasing the Utility of AI in Early Stages of R&D to Prove This Disruptive Technology’s Validity"
- 2:00 PM: Keinan will participate in the panel discussion: "Marrying Machine Learning Platforms with R&D Data to Streamline the Application of AI Technology"
- 3:15 PM: Addison will participate in the panel discussion "What’s the Future for AI Application and Collaboration and What Can we do Now to Maximize the Chance of Success?"
In addition participating in the panel discussion, Addison is available for meetings on the afternoon of July 26.
Cloud Pharmaceuticals continues to show leadership in the field of artificial intelligence by designing completely novel molecules across the broadest range of targets in the shortest amount of time in this new industry.
For information about the AI Innovation Summit please visit the event site. For information about Cloud Pharmaceuticals or to set up a meeting with a member of our team, please e-mail us.
About Cloud Pharmaceuticals, Inc.
Cloud Pharmaceuticals is committed to improving health and well-being through the computational design and rapid development of new therapies. Its proprietary Quantum Molecular Design process combines artificial intelligence (AI) and cloud computing to search virtual molecular space and applies along sophisticated molecular modeling to design novel drugs. The process enables faster drug development progress at lower cost and a higher success rate and better targeting of hard-to-drug indications. The company partners at all stages of drug development – from discovery through the clinic – and is building an extensive product pipeline that spans a wide range of indications.
Cloud Pharmaceuticals is committed to improving health and well-being through the computational design and rapid development of new therapies. Its proprietary Quantum Molecular Design process combines artificial intelligence (AI) and cloud computing to search virtual molecular space and applies along sophisticated molecular modeling to design novel drugs. The process enables faster drug development progress at lower cost and a higher success rate and better targeting of hard-to-drug indications. The company partners at all stages of drug development – from discovery through the clinic – and is building an extensive product pipeline that spans a wide range of indications.
###
